An unexplained death at a Russian plague research institute has prompted international scrutiny. The incident raises questions about laboratory safety, transparent reporting, and infection prevention preparedness while the cause remains unconfirmed.
|Articles|March 27, 2017
Gastric Acid Suppression Medications Increase Risk for Recurrence of Clostridium difficile Infection
Advertisement
Researchers at Mayo Clinic have found patients who use gastric suppression medications are at a higher risk for recurrent Clostridium difficile (C. diff) infection. C. diff is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. The study is published in JAMA Internal Medicine.
"In our study, we found that use of gastric acid suppression medications are associated with a statistically significant increased risk of development of recurrent C. diff in patients with a prior episode of C. diff," says Sahil Khanna, MBBS, a gastroenterologist at Mayo Clinic and senior author of the study.
Khanna says gastric suppression medications studied include proton pump inhibitors, such as omeprazole, and histamine 2 blockers, such as ranitidine, which are commonly prescribed and consumed over-the-counter medications for gastroesophageal reflux disease, peptic ulcer disease or dyspepsia.
In a systematic review and meta-analysis of 16 studies with 7,703 patients with C. diff, 1,525 developed recurrent C. diff. The rate of recurrent C. diff in patients with gastric suppression was 22.1 percent, compared to 17.3 percent in patients without gastric acid suppression.
Khanna urges caution in interpreting these findings due to variables not considered in the study, such as the underlying reason why the gastric acid suppressant was needed. However, he says the findings suggest that patients with C. diff who receive gastric acid suppressants may be at increased risk of C-diff recurrence. "It may be reasonable to re-evaluate the need for these medications in patients with . diff," Khanna says.
Source: Mayo Clinic
Advertisement
Related to this article
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.
This week's coverage in Infection Control Today centered on a common thread: the systems, partnerships, and data that let infection prevention teams catch problems before patients are harmed.
UPMC’s genomic surveillance initiative earned national recognition for patient safety. Alexander Sundermann, DrPH, CIC, FAPIC, AL-CIP, explains how the award could help infection preventionists secure leadership support and sustainable funding for earlier outbreak detection.
Knowing the protocol is only the beginning. In The Clean Bite, Sherrie Busby explores how explaining the why, addressing staff concerns, and creating clear procedures can help dental teams make infection control part of everyday practice.
What might infection prevention rounds miss when visible conditions dominate the conversation? Tommy Davis, PhD, CMIP, a member of ICT's executive advisory board, makes the case for structured observations of clinical workflows, shared accountability, and greater attention to environmental services staff’s insights.
A proposed $27.7 million reduction in AHRQ funding raises questions about support for infection prevention research and implementation. Here is what the September 25 announcement identifies, as well as what remains unknown about specific IPC programs.
Advertisement
Advertisement